Efficacy of AC‐T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis
International Journal of Breast Cancer · 2026-01 · 2026 (1)
DOI: 10.1155/ijbc/6630563 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Breast Cancer, online erschienen am 19.06.2026. Verfasst von Mehrzad Mirzania und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran,…. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Locally advanced breast cancer (LABC) remains a major therapeutic challenge, with neoadjuvant chemotherapy (NAC) serving as a cornerstone of management. However, direct evidence comparing the efficacy of sequential (AC‐T) and concurrent (TAC) anthracycline–taxane regimens in real‐world Middle Eastern populations remains scarce. This study is aimed at comparing the clinical outcomes of AC‐T and TAC in Iranian women with LABC.
Methods
A retrospective cohort study was conducted among 118 patients with Stage III breast cancer treated at Tehran, Iran. Patients received either AC‐T (doxorubicin/cyclophosphamide followed by paclitaxel; n = 70) or TAC (docetaxel/doxorubicin/cyclophosphamide; n = 48). Outcomes included pathological complete response (pCR), overall survival (OS), disease‐free survival (DFS), distant recurrence‐free survival (DRFS), and locoregional recurrence‐free survival (LRFS).
Results
Baseline demographic and clinical characteristics were comparable between groups. No significant difference in pCR rates was observed between the groups. The AC‐T regimen showed higher, though nonsignificant, OS at 3, 5, and 10 years (90%, 82%, and 71%, respectively) compared with TAC (83%, 74%, and 57%). Conversely, TAC demonstrated significantly superior 10‐year DRFS (62% vs. 45%, p = 0.019). DFS and LRFS were similar between regimens. Multivariable Cox regression analysis identified ER positivity as the only independent predictor of improved OS (HR = 0.42, 95% CI: 0.29–0.82, p = 0.012) and DFS (HR = 0.36, 95% CI: 0.18–0.73, p = 0.005), whereas the chemotherapy regimen was not independently associated with survival after adjustment for confounders.
Conclusion
Both AC‐T and TAC provided effective neoadjuvant control in LABC, with comparable survival outcomes. These findings support individualized regimen selection based on patient profile and tumor biology. Prospective studies are needed to refine region‐specific treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir.
- Faculty of Medicine, Bogomolets National Medical University (NMU), Kyiv, Ukraine.
- Cancer Research Center, Hamadan University of Medical Science (UMSHA), Hamadan, Iran.
ORCID-Profile: Mehdi Karimi, Masoud Mortezazadeh, Ahmad Khajeh-Mehrizi
Zitieren
APA
Mirzania, M., Anari, F., Emami, S. A. H., Roudini, K., Karimi, M., Saleh, K., Mortezazadeh, M., & Khajeh-Mehrizi, A. (2026). Efficacy of AC‐T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis. International Journal of Breast Cancer, 2026(1). https://doi.org/10.1155/ijbc/6630563
Vancouver
Mirzania M, Anari F, Emami SAH, Roudini K, Karimi M, Saleh K, et al. Efficacy of AC‐T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis. International Journal of Breast Cancer. 2026;2026(1). doi:10.1155/ijbc/6630563
BibTeX
@article{Mirzania2026,
author = {Mirzania, Mehrzad and Anari, Fatemeh and Emami, Seyed Amir Hossein and Roudini, Kamran and Karimi, Mehdi and Saleh, Kianmehr and Mortezazadeh, Masoud and Khajeh-Mehrizi, Ahmad},
title = {Efficacy of AC‐T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis},
journal = {International Journal of Breast Cancer},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijbc/6630563}
}
EUVIMED